Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovir
© 2019 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd..
BACKGROUND AND AIM: Loss of hepatitis B surface antigen (HBsAg) is an important goal in the treatment of chronic hepatitis B. We investigated whether switching from long-term entecavir (ETV) administration to tenofovir (TFV) (tenofovir alafenamide [TAF] or tenofovir disoproxil fumarate [TDF]) could contribute to the reduction of HBsAg levels.
METHODS: The degree of HBsAg reduction by 48 weeks in 30 patients following switching from ETV to TFV was compared with results from 147 patients who continued ETV as a control.
RESULTS: TFV group switched to TFV after mean 6.79 years of ETV administration. HBV-DNA levels remained below 1.0 log IU/mL in all cases in both groups during 48 weeks. Median HBsAg reduction at 48 weeks was 0.075 (-0.05 to 0.38) log/IU/mL in the TFV switch group, and 0.070 (-0.28 to 0.50) in the ETV continuation group, which was not statistically significant (p = 0.5). In a subgroup of hepatitis B e antigen negative patients whose HBsAg had not been reduced (HBsAg reduction ≤0 log IU/mL) in the 48 weeks prior to entry into the study, HBsAg reduction was significantly higher in the TFV switch group than in the ETV continuation group (0.15 [0.07-0.135] in TFV, 0.09 [-0.14 to 0.25] log IU/mL in ETV, p = 0.04).
CONCLUSION: Although HBsAg reduction is equivalent with ETV continuation and switching to TFV in all patients at 48 weeks, switching from ETV to TFV could provide an alternative therapeutic strategy toward HBsAg elimination in a specific subpopulation of patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
JGH open : an open access journal of gastroenterology and hepatology - 4(2020), 3 vom: 12. Juni, Seite 429-432 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tamaki, Nobuharu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic hepatitis B |
|---|
| Anmerkungen: |
Date Revised 14.04.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/jgh3.12273 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310938961 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310938961 | ||
| 003 | DE-627 | ||
| 005 | 20231225141156.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jgh3.12273 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1036.xml |
| 035 | |a (DE-627)NLM310938961 | ||
| 035 | |a (NLM)32514449 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tamaki, Nobuharu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovir |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.04.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2019 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. | ||
| 520 | |a BACKGROUND AND AIM: Loss of hepatitis B surface antigen (HBsAg) is an important goal in the treatment of chronic hepatitis B. We investigated whether switching from long-term entecavir (ETV) administration to tenofovir (TFV) (tenofovir alafenamide [TAF] or tenofovir disoproxil fumarate [TDF]) could contribute to the reduction of HBsAg levels | ||
| 520 | |a METHODS: The degree of HBsAg reduction by 48 weeks in 30 patients following switching from ETV to TFV was compared with results from 147 patients who continued ETV as a control | ||
| 520 | |a RESULTS: TFV group switched to TFV after mean 6.79 years of ETV administration. HBV-DNA levels remained below 1.0 log IU/mL in all cases in both groups during 48 weeks. Median HBsAg reduction at 48 weeks was 0.075 (-0.05 to 0.38) log/IU/mL in the TFV switch group, and 0.070 (-0.28 to 0.50) in the ETV continuation group, which was not statistically significant (p = 0.5). In a subgroup of hepatitis B e antigen negative patients whose HBsAg had not been reduced (HBsAg reduction ≤0 log IU/mL) in the 48 weeks prior to entry into the study, HBsAg reduction was significantly higher in the TFV switch group than in the ETV continuation group (0.15 [0.07-0.135] in TFV, 0.09 [-0.14 to 0.25] log IU/mL in ETV, p = 0.04) | ||
| 520 | |a CONCLUSION: Although HBsAg reduction is equivalent with ETV continuation and switching to TFV in all patients at 48 weeks, switching from ETV to TFV could provide an alternative therapeutic strategy toward HBsAg elimination in a specific subpopulation of patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a chronic hepatitis B | |
| 650 | 4 | |a entecavir | |
| 650 | 4 | |a hepatitis B surface antigen | |
| 650 | 4 | |a tenofovir | |
| 700 | 1 | |a Kurosaki, Masayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kirino, Sakura |e verfasserin |4 aut | |
| 700 | 1 | |a Yamashita, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Osawa, Leona |e verfasserin |4 aut | |
| 700 | 1 | |a Sekiguchi, Shuhei |e verfasserin |4 aut | |
| 700 | 1 | |a Hayakawa, Yuka |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Wan |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Mao |e verfasserin |4 aut | |
| 700 | 1 | |a Higuchi, Mayu |e verfasserin |4 aut | |
| 700 | 1 | |a Takaura, Kenta |e verfasserin |4 aut | |
| 700 | 1 | |a Maeyashiki, Chiaki |e verfasserin |4 aut | |
| 700 | 1 | |a Kaneko, Shun |e verfasserin |4 aut | |
| 700 | 1 | |a Yasui, Yutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuchiya, Kaoru |e verfasserin |4 aut | |
| 700 | 1 | |a Nakanishi, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Itakura, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Yuka |e verfasserin |4 aut | |
| 700 | 1 | |a Enomoto, Nobuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Izumi, Namiki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JGH open : an open access journal of gastroenterology and hepatology |d 2017 |g 4(2020), 3 vom: 12. Juni, Seite 429-432 |w (DE-627)NLM291146678 |x 2397-9070 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2020 |g number:3 |g day:12 |g month:06 |g pages:429-432 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jgh3.12273 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2020 |e 3 |b 12 |c 06 |h 429-432 | ||